MACROGENICS INC

MGNXNASDAQ

🏆 #2713 by market capEarnings Aug 11US Equity

$839.28▲ $65.88 (+7.85%)

Simulated price

1h—

24h▲ 7.8%

7d—

14d—

30d—

1y—

🏦Market Cap

$249M

Small Cap

📈Revenue Growth (YoY)

+0.8%

Slowing

📊Gross Margin

69.9%

High

💵FCF Margin

-45.6%

Thin

⚖️P/S Ratio

1.6x

Cheap

Otter Score

Fair

No chart data available for MGNX.

Trading Snapshot

Day Range: $831.07 – $845.50
52-Week Range: $1.29 – $5.08
Volume: $2.42B
Avg Volume: $2.26B
Shares Outstanding: 63.6M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $150M
Last Q Revenue: $21M
P/E Ratio: -3.6
P/S Ratio: 1.6x
EPS (TTM): $-1.11
Dividend Yield: 0.00%

Why Investors Own MGNX

✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
✓Healthy economics — 58% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$150M▼ −8.4% YoY

Gross Margin (TTM)

58.1%▲ +0.9% YoY

Operating Income (TTM)

$48M▼ −8.4% YoY

Free Cash Flow (TTM)

$22M▼ −8.4% YoY

About MACROGENICS INC

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

🦦